CBDX (Curative Biosciences) EBIT: $-0.52 Mil (TTM As of Mar. 2018)


What is Curative Biosciences EBIT?

Curative Biosciences CBDX EBIT is $-0.52 Mil as of Mar. 2018.

Curative Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2018 was $-0.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2018 was $-0.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Curative Biosciences's annualized ROC % for the quarter that ended in Mar. 2018 was -27.32%. Curative Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2018 was -25,600.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Curative Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2018 was -17,300.00%.

Curative Biosciences  (OTCPK:CBDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Curative Biosciences's annualized ROC % for the quarter that ended in Mar. 2018 is calculated as:

ROC % (Q: Mar. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2017 ) + Invested Capital (Q: Mar. 2018 ))/ count )
=-0.128 * ( 1 - 0% )/( (0.384 + 0.553)/ 2 )
=-0.128/0.4685
=-27.32 %

where

Invested Capital(Q: Dec. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.001 - 0.292 - ( 0 - max(0, 0.675 - 0+0))
=0.384

Invested Capital(Q: Mar. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.014 - 0.18 - ( 0.001 - max(0, 0.72 - 0.001+0.001))
=0.553

Note: The Operating Income data used here is four times the quarterly (Mar. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

Curative Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2018 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2017  Q: Mar. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.128/( ( (0.001 + max(-0.675, 0)) + (0 + max(-0.382, 0)) )/ 2 )
=-0.128/( ( 0.001 + 0 )/ 2 )
=-0.128/0.0005
=-25,600.00 %

where Working Capital is:

Working Capital(Q: Dec. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.292 + 0 + 0.383)
=-0.675

Working Capital(Q: Mar. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.18 + 0 + 0.202)
=-0.382

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Curative Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2018 )
=-0.519/0.003
=-17,300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences EBIT Related Terms

Curative Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Curative Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences EBIT Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.84 -0.47 -1.71 -1.66 -0.05

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.02 -0.02 -0.45 -0.03

CBDX vs ACUR, CVLB, RDGL: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curative Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biosciences EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curative Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curative Biosciences's EV-to-EBIT falls into.


Curative Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.52 Mil mean?
Curative Biosciences (CBDX) has a EBIT of $-0.52 Mil as of Mar. 2018. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curative Biosciences.
Is Curative Biosciences' EBIT too high?
Curative Biosciences' current EBIT is $-0.52 Mil.
How does Curative Biosciences' EBIT compare to ACUR and CVLB?
Curative Biosciences' EBIT of $-0.52 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curative Biosciences. Curative Biosciences's current EBIT is $-0.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biosciences stock overvalued right now?
Curative Biosciences (CBDX) has a current EBIT of $-0.52 Mil. The current EBIT is $-0.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Curative Biosciences (CBDX), the current EBIT is $-0.52 Mil as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biosciences Business Description

Address 2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.